Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 24, Issue 12, Pages 597-606Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2013.08.003
Keywords
-
Categories
Funding
- National Institutes of Health [P50 AG023501, F32 BL116197, F31 AG034793]
- Consortium for Frontotemporal Dementia Research
- Gladstone Institutes
- National Center for Research Resources [RR18928]
- American Diabetes Association
Ask authors/readers for more resources
Progranulin is a widely expressed, cysteine-rich, secreted glycoprotein originally discovered for its growth factor-like properties. Its subsequent identification as a causative gene for frontotemporal dementia (FTD), a devastating early-onset neurodegenerative disease, has catalyzed a surge of new discoveries about progranulin function in the brain. More recently, progranulin was recognized as an adipokine involved in diet-induced obesity and insulin resistance, revealing its metabolic function. We review here progranulin biology in both neurodegenerative and metabolic diseases. In particular, we highlight the growth factor-like, trophic, and antiinflammatory properties of progranulin as potential unifying themes in these seemingly divergent conditions. We also discuss potential therapeutic options for raising progranulin levels to treat progranulin-deficient FTD, as well as the possible consequences of such treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available